Uterine Fibroids Treatment Market Report 2026

The uterine fibroids treatment market size has grown strongly in recent years. It will grow from $4.43 billion in 2025 to $4.85 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to improved awareness of uterine fibroid symptoms, availability of surgical treatment options, expansion of gynecological care facilities, increasing diagnosis rates through imaging, growth of women’s healthcare services.

The uterine fibroids treatment market size is expected to see strong growth in the next few years. It will grow to $7.08 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing adoption of non-surgical treatment alternatives, rising demand for fertility-preserving therapies, expansion of outpatient gynecological procedures, growing investment in women’s health research, increasing use of image-guided therapies. Major trends in the forecast period include increasing adoption of minimally invasive treatment procedures, growing use of hormonal and non-hormonal therapies, rising preference for uterus-preserving treatments, expansion of advanced imaging-guided interventions, enhanced patient-centric treatment planning.

The high prevalence of uterine fibroids among women is expected to drive the growth of the uterine fibroids treatment market in the coming years. Uterine fibroids are non-cancerous growths that develop in the uterus and can lead to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel. Treatments for uterine fibroids work by blocking the production of estrogen and progesterone, stopping menstruation, and improving anemia. For example, in September 2024, Oxford Academic, a UK-based publisher of the journal Human Reproduction, reported that an estimated 7.3% of Australian women had been diagnosed with uterine fibroids by age 45-49, with the highest age-specific incidence among women aged 40-44 (5 new cases per 1,000 person-years). Therefore, the high prevalence of uterine fibroids among women worldwide is driving the growth of the uterine fibroids treatment market.

Key companies in the uterine fibroids treatment market are focusing on product innovations, such as non-hormonal therapies and flexible dosing options, to meet diverse patient needs and maintain a competitive edge. Non-hormonal treatments for uterine fibroids, including GnRH receptor antagonists, work by inhibiting gonadotropin-releasing hormone at pituitary receptors, thereby reducing estrogen production and relieving symptoms such as heavy bleeding and pelvic pain. For instance, in September 2024, Kissei Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched YSELTY, a treatment for uterine fibroids, marking a notable advancement in women’s healthcare. YSELTY provides a non-hormonal option with flexible dosing tailored to individual patient needs, especially for those with severe fibroid symptoms. As a GnRH receptor antagonist, YSELTY reduces estrogen production by inhibiting gonadotropin-releasing hormone at pituitary receptors, effectively alleviating bleeding and pain.

In January 2025, Hologic Inc., a US-based women’s health and medical technology company, acquired Gynesonics Inc. for approximately $350 million. This acquisition aims to enhance Hologic’s portfolio of minimally invasive gynecological solutions by integrating Gynesonics’ Sonata System, an incisionless, ultrasound-guided radiofrequency ablation technology designed to treat symptomatic uterine fibroids. Gynesonics Inc. is a US-based medical device company specializing in transcervical, uterus-sparing therapeutic systems for women with fibroids.

Major companies operating in the uterine fibroids treatment market are Gynesonics Inc., Medtronic plc, Boston Scientific Corporation, Karl Storz GmbH, Pfizer Inc., Abbvie Inc., Richard Wolf GmbH, CooperSurgical Inc., Olympus Corporation, Myovant Sciences GmbH, Insightec Ltd., Hologic Inc., Obseva SA, Eli Lilly and Company, GlaxoSmithKline plc, Stryker Corporation, Smith & Nephew plc, Minerva Surgical Inc., Ethicon Inc., Cook Medical LLC, C.R. Bard Inc., Biomerics LLC, Visionsense Corp., Halt Medical Inc., Acessa Health Inc., Blue Endo, LiNA Medical ApS, Merit Medical Systems Inc., Allergan plc, Astellas Pharma Inc.

North America was the largest region in the uterine fibroids treatment market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uterine fibroids treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uterine fibroids treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the uterine fibroids treatment market by increasing costs of imported medical devices, embolization materials, surgical instruments, imaging equipment, and pharmaceutical ingredients. Hospitals and ambulatory surgical centers in North America and Europe are most impacted due to reliance on imported gynecological devices, while Asia-Pacific faces pricing pressure on drug imports. These tariffs are raising procedural costs and influencing treatment accessibility. However, they are also encouraging local manufacturing of medical devices, regional pharmaceutical production, and innovation in cost-effective treatment solutions for uterine fibroids.

The uterine fibroids treatment market research report is one of a series of new reports that provides uterine fibroids treatment market statistics, including uterine fibroids treatment industry global market size, regional shares, competitors with a uterine fibroids treatment market share, detailed uterine fibroids treatment market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroids treatment industry. This uterine fibroids treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Uterine fibroids treatment refers to medical procedures aimed at managing uterine fibroids. Uterine fibroids are non-cancerous growths that form in the uterus and may lead to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel.

The primary types of uterine fibroids treatment include subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids. Subserosal fibroids are benign growths located on the outer wall of the uterus, and pedunculated fibroids are those directly attached to the uterus. Treatments include hormone therapy, androgens, gonadotropin-releasing hormone antagonists, uterine artery embolization, myomectomy, and hysterectomy, administered to end users such as hospitals, ambulatory surgical centers, and others.

The uterine fibroids treatment market includes revenues earned by entities by providing medical, surgical, and radiologically guided therapies available as treatments for uterine fibroids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.